Table 4 Changes in TRACP-5b levels during the study period
From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study
Patient | Sex | Age (years) | Baseline iPTH (pg/mL) | Baseline serum calcium (mEq/L) | Baseline BALP (μg/L) | Baseline TRACP-5b (mU/dL) | End of study TRACP-5b (mU/dL) | Changing levels of TRACP-5b (mU/dL) |
|---|---|---|---|---|---|---|---|---|
1 | Female | 80 | 69 | 8.5 | 12.6 | 1110 | 656 | − 454 |
2 | Male | 68 | 279 | 9.4 | 15.5 | 656 | 754 | + 98 |
3 | Male | 89 | 478 | 9.2 | 9.6 | 346 | 256 | − 90 |
4 | Male | 57 | 246 | 8.8 | 12.1 | 641 | 584 | − 57 |
5 | Male | 67 | 238 | 8.8 | 17.6 | 1070 | 946 | − 124 |
6 | Female | 71 | 474 | 8.4 | 19.3 | 633 | 366 | − 267 |
7 | Male | 92 | 280 | 8.2 | 11.5 | 933 | 684 | − 249 |
8 | Male | 83 | 50 | 9.3 | 6.5 | 425 | 195 | − 230 |
9 | Male | 78 | 42 | 8.6 | 9.7 | 301 | 179 | − 122 |
10 | Female | 85 | 773 | 10.1 | 36.8 | 1400 | 1110 | − 290 |
11 | Female | 88 | 167 | 8.4 | 31.9 | 986 | 558 | − 428 |
12 | Male | 78 | 65 | 8.7 | 10.1 | 338 | 328 | − 10 |
13 | Male | 79 | 542 | 8.1 | 41.6 | 1370 | 1680 | + 310 |